Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa L Johnson

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Oncology (Williston Park, N.Y.)|June 11, 2005
Emerging targeted therapies for breast cancerMelissa L Johnson, Andrew D Seidman
The Oncologist|February 10, 2015
Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancerRyan D Gentzler, Melissa L Johnson
Seminars in Oncology|February 26, 2014
Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancerMelissa L Johnson, Jyoti D Patel
Journal of Patient-Centered Research and Reviews|August 16, 2019
Team-Based Care and Patient Satisfaction in the Hospital Setting: A Systematic ReviewKristen K Will, Melissa L Johnson, Gerri Lamb
Lung Cancer (Amsterdam, Netherlands)|December 7, 2010
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitorsMarie Brevet, Melissa L Johnson, Christopher G Azzoli, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 13, 2022
More to the RAS Story: KRAS<sup>G12C</sup> Inhibition, Resistance Mechanisms, and Moving Beyond KRAS<sup>G12C</sup>Caressa D Lietman, Melissa L Johnson, Frank McCormick, et al.
Cancer Research|January 9, 2026
MTAP Deletion in Oncogenesis: A Synthetic Lethality ScenarioJordi Rodon, Melissa L Johnson, Ben George, et al.
Targeted Oncology|November 10, 2024
Delayed Separation of Kaplan-Meier Curves is Commonly Observed in Studies of Advanced/Metastatic Solid Tumors Treated with Anti-PD-(L)1 Therapy: Systematic Review and Meta-AnalysisDo-Youn Oh, Nana Rokutanda, Magdalena Żotkiewicz, et al.
Oncology and Therapy|December 18, 2024
A Podcast Discussion on the Intracranial Efficacy of Antibody-Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain MetastasesMelissa L Johnson, Jessica J Lin, Adrienne Boire, et al.
Cancer|August 27, 2014
The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteriaRyan D Gentzler, Sarah E Yentz, Melissa L Johnson, et al.
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Oncology (Williston Park, N.Y.)|June 11, 2005
Emerging targeted therapies for breast cancerMelissa L Johnson, Andrew D Seidman
The Oncologist|February 10, 2015
Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancerRyan D Gentzler, Melissa L Johnson
Seminars in Oncology|February 26, 2014
Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancerMelissa L Johnson, Jyoti D Patel
Journal of Patient-Centered Research and Reviews|August 16, 2019
Team-Based Care and Patient Satisfaction in the Hospital Setting: A Systematic ReviewKristen K Will, Melissa L Johnson, Gerri Lamb
Lung Cancer (Amsterdam, Netherlands)|December 7, 2010
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitorsMarie Brevet, Melissa L Johnson, Christopher G Azzoli, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 13, 2022
More to the RAS Story: KRAS<sup>G12C</sup> Inhibition, Resistance Mechanisms, and Moving Beyond KRAS<sup>G12C</sup>Caressa D Lietman, Melissa L Johnson, Frank McCormick, et al.
Cancer Research|January 9, 2026
MTAP Deletion in Oncogenesis: A Synthetic Lethality ScenarioJordi Rodon, Melissa L Johnson, Ben George, et al.
Targeted Oncology|November 10, 2024
Delayed Separation of Kaplan-Meier Curves is Commonly Observed in Studies of Advanced/Metastatic Solid Tumors Treated with Anti-PD-(L)1 Therapy: Systematic Review and Meta-AnalysisDo-Youn Oh, Nana Rokutanda, Magdalena Żotkiewicz, et al.
Oncology and Therapy|December 18, 2024
A Podcast Discussion on the Intracranial Efficacy of Antibody-Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain MetastasesMelissa L Johnson, Jessica J Lin, Adrienne Boire, et al.
Cancer|August 27, 2014
The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteriaRyan D Gentzler, Sarah E Yentz, Melissa L Johnson, et al.
Pageof 10